<DOC>
	<DOC>NCT00737477</DOC>
	<brief_summary>This single-arm study will assess the efficacy and safety of monthly administration of SC Mircera for the maintenance of hemoglobin levels in participants with chronic kidney disease on peritoneal dialysis. Participants currently receiving maintenance treatment with SC erythropoietin stimulating agents (ESAs) will receive monthly SC injections of Mircera, with the starting dose derived from the last weekly ESA they had been receiving.</brief_summary>
	<brief_title>A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Adults greater than or equal to (≥) 18 years of age Chronic kidney diseaserelated anemia on peritoneal dialysis for ≥3 months Continuous SC maintenance stable ESA therapy for 4 weeks prior to study start Transfusion of red blood cells during previous 8 weeks Poorly controlled hypertension requiring interruption of ESA treatment in previous 6 months Significant acute or chronic bleeding during previous 8 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>